Effect of avelumab on 89 refined immune cell subsets

PostSubsetIncreaseMinimal changeDecreaseUnadjusted P-valueDirectionHolm adjusted P-value
1 cyclePD-1+ ICOS+ CD412 (63%)5 (26%)2 (11%)0.01810.5611
PD-1+ Tregs12 (63%)5 (26%)2 (11%)0.01410.0705
Functional intermediate NK10 (53%)6 (31%)3 (16%)0.04010.5213
3 cyclesFunctional intermediate NK1 (7%)4 (29%)9 (64%)0.02950.4130
9 cyclesCTLA-4+ EM CD89 (56%)6 (38%)1 (6%)0.02500.6250
Functional intermediate NK2 (12%)4 (25%)10 (63%)0.03860.5018
PD-1+ pDC10 (63%)2 (12%)4 (25%)0.03350.1005
CD16+ MDSC9 (56%)5 (31%)2 (13%)0.00920.1288
gMDSC11 (69%)2 (12%)3 (19%)0.01310.1703
CD16+ gMDSC10 (62%)3 (19%)3 (19%)0.01550.1705
PD-1+ lin neg MDSC10 (62%)4 (25%)2 (13%)0.01820.1820

The frequency of 89 refined immune cell subsets was examined pre-therapy and post-1 cycle (n=19), 3 cycles (n=14), and 9 cycles (n=16) of avelumab. Table displays subsets that met criteria as a potentially biologically relevant trend. Results are displayed as the number of patients (percentage of total patients) with an increase of more than 25%, minimal change of less than 25%, and a decrease of more than 25% compared to pre-therapy. Unadjusted p-values (direction of change compared to pre-therapy) were calculated using the Wilcoxon matched-pairs signed rank test, and Holm adjustment was made for the number of subsets within the classic subsets with a frequency above 0.01% of PBMC

EM effector memory, gMDSC granulocytic MDSC, ICOS inducible T cell co-stimulator, lin neg MDSC lineage negative MDSC, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PD-1 programmed cell death protein 1, Tregs regulatory T cells